Axios Science on MSN3mon
Seattle firm targets hepatitis B through gene-editing
A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses ...
Nature20d
Hepatitis C Virus Infection and Immune Response
Hepatitis C virus (HCV ... Finally, innovative vaccine candidates, such as nanoparticle-based vaccines displaying permuted E1E2 glycoproteins, have shown promise in eliciting robust neutralizing ...
precisionmedicineonline1d
FDA Clears Lion TCR to Begin Phase II Trial of TCR T-Cell Therapy in HBV-Related Liver Cancer
The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.
Medscape2mon
Lipid-based Nanoparticles in the Systemic Delivery of siRNA
DSPC:Chol:PEG–C–DMA:DLin–DMA (20:48:2:30)–siRNA Hepatitis B virus (yes ... and lower toxicity in comparison with inorganic nanoparticles and viral vectors. Function-engineerable ...
technologynetworks5mon
The Immune System – News and Features
Lipoxen joins with Nottingham University to deliver antiviral drugs direct to the liver by means of nanoparticles for the treatment of viral hepatitis. Lipoxen joins with Nottingham University to ...